
North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Health Information Designs, LLC

Welcome to the “North Dakota Medicaid Pharmacy Program Quarterly News,” a pharmacy newsletter presented by the North Dakota Department of Human Services and published by Health Information Designs, LLC. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Human Services has contracted with Health Information Designs, LLC (HID) to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit www.hidndmedicaid.com, or call HID at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup. This allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

This newsletter provides information regarding significant new dosage forms introduced in 2014. Also included is the top 25 drug list of second quarter 2014 by cost and claims count.

The North Dakota Medicaid Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, or to make comments, please contact Health Information Designs, LLC at (334) 502-3262, call toll free at 1-800-225-6998, or e-mail us at info@hidinc.com.



Helpful Numbers

PA Help Desk 866-773-0695
To fax PAs 866-254-0761
To report adverse reactions 800-FDA-1088

Inside this issue:	Page
Welcome	1
Helpful Numbers	1
Significant New Dosage Forms-2014	2
Top 25 by Cost and Claims Count	3
Health Information Designs, LLC	4

Visit HID's North Dakota Department of Human Services Prior Authorization Webpage, www.hidndmedicaid.com.

Significant New Dosage Forms 2014

Brand/Generic	Description
Acticlate (doxycycline hyclate)	New antibiotic formulation.
Afrezza (insulin human)	New inhaled rapid-acting insulin for diabetes.
Arnuity Ellipta (fluticasone furoate)	A corticosteroid oral inhaler for maintenance treatment of asthma.
Aveed (testosterone)	New injectable testosterone replacement requiring less frequent
Bunavail (buprenorphine/naloxone)	A buccal film formulation for maintenance treatment of opioid de-
Contrave (naltrexone/bupropion)	A combination opioid antagonist and antidepressant for weight
Epanova (omega-3-carboxylic acids)	An omega-3 fatty acid formulation for severe hypertriglyceridemia.
Evzio (naloxone)	New auto-injector formulation for emergency treatment of opioid
Hemangeol (propranolol)	An oral solution formulation for infantile hemangioma.
Incruse Ellipta (umeclidinium)	New anticholinergic oral inhaler for maintenance treatment of
Invokamet (canagliflozin/metformin)	New combination SGLT2 inhibitor and biguanide for type 2 diabetes.
Natesto (testosterone)	A nasal gel formulation for androgen replacement therapy in men.
Omidria (phenylephrine/ketorolac)	For ophthalmic irrigation during cataract surgery or intraocular lens
Omtryg (omega-3-acid ethyl esters A)	An omega-3 fatty acid formulation for severe hypertriglyceridemia.
Purixan (mercaptopurine)	An oral suspension formulation for acute lymphoblastic leukemia.
Qudexy XR (topiramate)	New extended-release formulation antiepileptic drug.
Rasuvo (methotrexate)	A subcutaneous injection for rheumatoid arthritis and severe psori-
Ryanodex (dantrolene sodium)	New injectable suspension formulation for prevention and treat-
Targiniq ER (oxycodone/naloxone)	Combination opioid agonist and antagonist for severe pain.
Tivorbex (indomethacin)	New low-dose formulation for mild to moderate acute pain in
Triumeq (abacavir/dolutegravir/lamivudine)	New combination integrase strand transfer inhibitor and nucleoside analogue reverse transcriptase inhibitors for HIV-1 infection.
Vogelxo (testosterone)	New topical gel formulation for androgen replacement therapy in
Xartemis XR (oxycodone/acetaminophen)	New extended-release combination opioid/acetaminophen product for acute, severe pain.

Top 25 Drugs for 2nd Quarter 2014

Top 25 Drugs by Number of Claims			Top 25 Drugs by Total Claims Cost		
Drug Name	Total Claims	Paid Amount	Drug Name	Total Claims	Paid Amount
HYDROCODONE-APAP	4,496	147,923.72	ABILIFY	1,103	724,811.13
AMOXICILLIN	3,483	97,048.11	METHYLPHENIDATE ER	2,125	292,734.84
OMEPRAZOLE	2,988	45,301.39	SOVALDI	11	278,942.42
PROVENTIL HFA	2,626	208,308.48	VYVANSE	1,484	242,945.32
AZITHROMYCIN	2,227	64,405.87	HELIXATE FS	10	235,309.56
SERTRALINE HCL	2,190	33,807.97	PROVENTIL HFA	2,626	208,308.48
METHYLPHENIDATE ER	2,125	292,734.84	INTUNIV	982	192,837.13
GABAPENTIN	2,109	89,231.00	ADVAIR DISKUS	627	187,134.28
LEVOTHYROXINE	2,067	32,154.69	LYRICA	672	184,488.57
FLUOXETINE HCL	2,001	22,927.92	DEXTROAMPH-AMPHET	1,390	166,421.58
LISINOPRIL	1,935	41,657.71	LANTUS SOLOSTAR	491	166,346.66
MONTELUKAST	1,883	50,002.54	DULOXETINE HCL	940	165,044.03
TRAZODONE HCL	1,833	17,741.25	NOVOLOG FLEXPEN	395	156,724.23
TRAMADOL HCL	1,720	59,043.99	HYDROCODONE-APAP	4,496	147,923.72
AMOX TR-POT CLAV	1,563	68,194.21	BUDESONIDE	489	143,133.65
VYVANSE	1,484	242,945.32	FREESTYLE LITE STRIPS	1,013	141,254.98
CLONIDINE HCL	1,484	14,502.90	STRATTERA	614	136,363.82
METFORMIN HCL	1,427	24,746.01	SEROQUEL XR	273	121,852.75
RISPERIDONE	1,406	22,307.99	LATUDA	148	119,058.97
IBUPROFEN	1,399	76,928.46	COPAXONE	23	118,327.74
DEXTROAMPH-AMPHET	1,390	166,421.58	LEVEMIR FLEXPEN	295	115,834.55
CLONAZEPAM	1,386	23,189.74	ENBREL	39	98,198.68
METHYLPHENIDATE	1,375	72,003.06	AMOXICILLIN	3,483	97,048.11
BUPROPION XL	1,335	32,949.43	HUMALOG	232	91,938.89
QUETIAPINE	1,297	23,121.35	GABAPENTIN	2,109	89,231.00
Top 25 by Claims Count	49,229	1,969,599.53	Top 25 by Claims Cost	26,070	4,622,215.09



Health Information Designs, LLC is the most experienced and qualified provider of drug utilization review and pharmacy support services in the country. We specialize in helping our clients promote clinically appropriate and cost-effective prescribing, dispensing, and utilization of prescription drugs.

Health Information Designs, LLC was founded in 1976 with a mission to improve patient care and contain costs for state Medicaid agencies by providing drug utilization review (DUR) services. In 1997, HID was acquired by HDI Solutions and subsequently has experienced strong and steady growth as a premium healthcare analytics and pharmacy support services provider. HID is the industry leader in providing comprehensive prescription drug monitoring programs. Currently, HID works with clients in 30 states, including 16 Medicaid agencies, 22 Boards of Pharmacy and state health agencies, and several private healthcare benefit management organizations. The work performed by HID has a daily impact on the healthcare of more than 115 million Americans.

**HEALTH
INFORMATION DESIGNS**

391 Industry Drive
Auburn, AL 36832
Tel: 800-748-0130
Fax: 800-748-0116

PRST STD
U.S. Postage